Anidulafungin in Treatment of Experimental Invasive Infection by Candida parapsilosis: In VitroActivity, (1→3)-β-d-Glucan and Mannan Serum Levels, Histopathological Findings, and In VivoEfficacy

ABSTRACTWe have evaluated the in vitroactivity of anidulafungin (AFG) against 31 strains of Candida parapsilosissensu stricto by using broth microdilution, disk diffusion, and minimal fungicidal concentration (MFC) determination procedures. The two first methods showed a high level of activity of the drug, while MFCs were 1 to 5 dilutions higher than their corresponding MICs. To assess if MICs were predictive of in vivooutcomes, six strains representing different AFG MICs (0.12 to 2 μg/ml) were tested in a murine model of disseminated infection treated with different doses of the drug (1, 5, or 10 mg/kg of body weight). AFG was able to prolong the survival of mice infected with all the strains tested but was able to reduce the tissue burden of those mice infected only with the strains that showed the lowest MIC (0.12 μg/ml).